Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations-Reference-Cited by-同舟云学术

Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations

Published:2021-08 Issue:11 Volume:13 Page:941-952
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Davis Alexander P¹,Cooper Wendy A²³⁴,Boyer Michael¹⁵,Lee Jenny H¹⁶,Pavlakis Nick⁵⁷⁸,Kao Steven C¹⁵⁹

Affiliation:

1. Department of Medical Oncology, Chris O'Brien Lifehouse, 119-143 Missenden Road, Camperdown, NSW 2050, Australia

2. Tissue Pathology & Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia

3. Sydney Medical School, University of Sydney, Sydney, NSW 2050, Australia

4. School of Medicine, Western Sydney University, Sydney, NSW 2571, Australia

5. Sydney Medical School, University of Sydney, NSW 2006, Australia

6. Faculty of Medicine & Health, Macquarie University, NSW 2109, Australia

7. Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia

8. Genesis Care St Leonards, St Leonards, NSW 2065, Australia

9. Asbestos Disease Research Institute, Concord, NSW 2139, Australia

Abstract

KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No KRAS specific therapy has been approved by the US FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. It is unclear whether KRAS mutations predict outcomes with immunotherapy; however, there is emerging data suggesting improved outcomes in patients with a TP53 comutation and worse outcomes in patients with a STK11/LKB1 or KEAP1 comutation.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2021-0090

Reference101 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

3. Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature

4. Clinical Features of 5,628 Primary Lung Cancer Patients

5. The Effect of Advances in Lung-Cancer Treatment on Population Mortality

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review;Cancers;2024-01-26

2. Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2023-12

3. Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer;Frontiers in Oncology;2023-11-09

4. A cellular and spatial atlas ofTP53-associated tissue remodeling in lung adenocarcinoma;2023-06-29

5. Recent progress in targeted therapy for non-small cell lung cancer;Frontiers in Pharmacology;2023-02-21